EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Targeting Tumor‐Associated Carbonic Anhydrases in Photothermal Therapy

Sébastien Clément iD, Sébastien Richeter iD, Jean-Yves Winum iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400893 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, 2025. Verfasst von Sébastien Clément und 2 weiteren Autor:innen. Beteiligte Einrichtung: ICGM, Univ Montpellier, CNRS, ENSCM, Montpellier, France. Hauptthemen laut MEDLINE: Carbonic Anhydrases, Neoplasms, Carbonic Anhydrase Inhibitors, Photothermal Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Montpellier, CNRS, French Ministry of Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor‐associated human carbonic anhydrases (hCAs), particularly isoforms hCA IX and hCA XII, are overexpressed in hypoxic regions of solid tumors and play a crucial role in regulating pH homeostasis, promoting cancer cell survival and enhancing invasiveness. These enzymes have emerged as promising therapeutic targets in cancer treatment, including photothermal therapy (PTT). PTT is a minimally invasive technique that uses light‐absorbing agents to convert near‐infrared (NIR) light into heat, effectively inducing localized hyperthermia and promoting cancer cell apoptosis. Recent advances in the design of hCA‐targeted photothermal agents have shown promise in selectively targeting and ablating cancer cells while sparing healthy tissues. We explore here recent advancements in developing combination therapies that integrate hCA‐targeted strategies with PTT for tumor treatment. By focusing on tumor‐associated isoforms hCA IX and hCA XII, we underscore the potential of hCA inhibition to enhance both the efficacy and specificity of PTT in cancer therapy. We also address critical challenges and outline future directions, emphasizing the need to improve the biocompatibility, stability, and clinical translation of hCA‐targeted photothermal agents. This mini review highlights the promise of combining hCA inhibition with PTT as an innovative therapeutic approach, aiming to advance more precise and effective cancer treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic AnhydrasesNeoplasmsCarbonic Anhydrase InhibitorsPhotothermal TherapyAntineoplastic AgentsHumansAnimals

Stichwörter der Autor:innen

CancerCarbonic anhydrase inhibitorsPhotodynamic therapyPhotothermal therapySulfonamide

Substanzen

Carbonic AnhydrasesCarbonic Anhydrase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • ICGM, Univ Montpellier, CNRS, ENSCM, Montpellier, France.
  • IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France.

ORCID-Profile: Sébastien Clément, Sébastien Richeter, Jean-Yves Winum

Förderung

  • University of Montpellier
  • CNRS
  • French Ministry of Research
  • Ligue contre le Cancer
  • Université de Montpellier

Zitieren

APA

Clément, S., Richeter, S., & Winum, J. Y. (2025). Targeting Tumor‐Associated Carbonic Anhydrases in Photothermal Therapy. ChemMedChem. https://doi.org/10.1002/cmdc.202400893

Vancouver

Clément S, Richeter S, Winum JY. Targeting Tumor‐Associated Carbonic Anhydrases in Photothermal Therapy. ChemMedChem. 2025. doi:10.1002/cmdc.202400893

BibTeX
@article{Clment2025,
  author = {Clément, Sébastien and Richeter, Sébastien and Winum, Jean-Yves},
  title = {Targeting Tumor‐Associated Carbonic Anhydrases in Photothermal Therapy},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400893}
}
Kostenlos starten →